Clinical Outcomes with First-Line Chemotherapy in a Large Retrospective Study of Patients with Metastatic Pancreatic Cancer Treated in a US Community Oncology Setting

• DOI: 10.1007/s40801-018-0137-x
• Publication Date: 2018-06-26T03:25:56Z
• Authors: Thomas H. Cartwright; Monika Parisi; Janet L. Espirito; Thomas W. Wilson; Corey Pelletier; Manish Patel; Hani M. Babiker
• Keywords: Clinical Oncology

The combination chemotherapy regimens of nab-paclitaxel plus gemcitabine (nab-p + G) and FOLFIRINOX (FFX) have each demonstrated improved survival compared with monotherapy in clinical trials for metastatic pancreatic cancer; however, limited comparative data exist. objective this study was to compare patient characteristics outcomes including time treatment failure overall patients cancer receiving first-line the community. We conducted a retrospective, multi-site, observational cohort nab-p G, FFX, or between April 2013 October 2015, using from iKnowMed electronic health record database. Patients on other diagnoses were excluded. Time assessed by Kaplan–Meier methods. Four hundred eighty-six met selection criteria, 255 159 72 patients. Median age 61, 68, 73 years patients, respectively (p < 0.01 G vs. FFX). Eastern Cooperative Oncology Group performance status 0–1 91% 77% 68% For FFX cohorts, respectively, 3.7 4.3 months (log-rank p = 0.25); OS 9.8 11.4 0.38). Among 0–1, 4.2 0.47); 12.1 vs 0.68). older had worse than not observed be significantly different Results similar after stratifying status.